Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background—: Angiotensin receptor neprilysin inhibitors (ARNi), beyond blocking angiotensin II signaling, augment natriuretic peptides by inhibiting their breakdown by neprilysin. The myocardial effects of ARNi have been little studied until recently. We hypothesized that LCZ696 attenuates left ventricular (LV) remodeling after experimental myocardial infarction (MI), and that this may be contributed to by inhibition of hypertrophy and fibrosis in cardiac cells. Methods and Results—: One week after MI, adult male Sprague–Dawley rats were randomized to treatment for 4 weeks with LCZ696 (68 mg/kg body weight perorally; MI-ARNi, n=11) or vehicle (MI-vehicle, n=6). Five weeks after MI, MI-ARNi versus MI-vehicle demonstrated lower LV end-diastolic diameter (by echocardiography; 9.7±0.2 versus 10.5±0.3 mm), higher LV ejection fraction (60±2 versus 47±5%), diastolic wall strain (0.23±0.02 versus 0.13±0.02), and circular strain (−9.8±0.5 versus −7.3±0.5%; all P <0.05). LV pressure–volume loops confirmed improved LV function. Despite similar infarct size, MI-ARNi versus MI-vehicle had lower cardiac weights ( P <0.01) and markedly reduced fibrosis in peri-infarct and remote myocardium. Angiotensin II–stimulated incorporation of 3[H]leucine in cardiac myocytes and 3[H]proline in cardiac fibroblast was used to evaluate hypertrophy and fibrosis, respectively. The neprilysin inhibitor component of LCZ696, LBQ657, inhibited hypertrophy but not fibrosis. The angiotensin receptor blocker component of LCZ696, valsartan inhibited both hypertrophy and fibrosis. Dual valsartan+LBQ augmented the inhibitory effects of valsartan and the highest doses completely abrogated angiotensin II–mediated effects. Conclusions—: LCZ696 attenuated cardiac remodeling and dysfunction after MI. This may be contributed to by superior inhibition of LCZ696 on cardiac fibrosis and cardiac hypertrophy than either stand-alone neprilysin inhibitor or angiotensin receptor blocker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Heart Disease and Stroke Statistics—2014 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., et al. (2014) · Circulation · doi:10.1161/01.cir.0000441139.02102.80 · Cited by 5,215
de Bold, A. J., Borenstein, H. B., Veress, A. T., & Sonnenberg, H. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90370-2 · Cited by 3,148
Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts
Bristow, M. R., Ginsburg, R., Minobe, W., Cubicciotti, R. S., Sageman, W. S., Lurie, K., Billingham, M. E., Harrison, D. C., & Stinson, E. B. (1982) · New England Journal of Medicine · doi:10.1056/nejm198207223070401 · Cited by 2,270
Noninvasive Myocardial Strain Measurement by Speckle Tracking Echocardiography
Amundsen, B. H., Helle-Valle, T., Edvardsen, T., Torp, H., Crosby, J., Lyseggen, E., Støylen, A., Ihlen, H., Lima, J. A. C., Smiseth, O. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.040 · Cited by 1,252
Solomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Effects of synthetic atrial natriuretic factor on renal function and renin release
Burnett, J. C. J., Granger, J. P., & Opgenorth, T. J. (1984) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1984.247.5.f863 · Cited by 659
Packer, M., Califf, R. M., Konstam, M. A., Krum, H., McMurray, J. J., Rouleau, J.-L., & Swedberg, K. (2002) · Circulation · doi:10.1161/01.cir.0000029801.86489.50 · Cited by 621
Self-citationRuilope, L. M., Dukat, A., Böhm, M., Lacourcière, Y., Gong, J., & Lefkowitz, M. P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61966-8 · Cited by 599
Kostis, J. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.09.014 · Cited by 579
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft052 · Cited by 457
Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes?
Lekawanvijit, S., Adrahtas, A., Kelly, D. J., Kompa, A. R., Wang, B. H., & Krum, H. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp574 · Cited by 315
Self-citationKario, K., Sun, N., Chiang, F.-T., Supasyndh, O., Baek, S. H., Inubushi-Molessa, A., Zhang, Y., Gotou, H., Lefkowitz, M., & Zhang, J. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.02002 · Cited by 233
WRITING COMMITTEE MEMBERS, Radford, M. J., Arnold, J. M. O., Bennett, S. J., Cinquegrani, M. P., Cleland, J. G. F., Havranek, E. P., Heidenreich, P. A., Rutherford, J. D., Spertus, J. A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.170073 · Cited by 195
(2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v122403 · Cited by 191
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.115 · Cited by 175
Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension
Bevan, E. G., Connell, J. M. C., Doyle, J., Carmichael, H. A., Davies, D. L., Lorimer, A. R., & Mclnnes, G. T. (1992) · Journal of Hypertension · doi:10.1097/00004872-199207000-00002 · Cited by 175
Ohtani, T., Mohammed, S. F., Yamamoto, K., Dunlay, S. M., Weston, S. A., Sakata, Y., Rodeheffer, R. J., Roger, V. L., & Redfield, M. M. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs135 · Cited by 169
von Lueder, T. G., Sangaralingham, S. J., Wang, B. H., Kompa, A. R., Atar, D., Burnett, J. C. J., & Krum, H. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000289 · Cited by 144
Self-citationCardiotrophin-1 Stimulation of Cardiac Fibroblast Growth
Tsuruda, T., Jougasaki, M., Boerrigter, G., Huntley, B. K., Chen, H. H., D’Assoro, A. B., Lee, S. C., Larsen, A. M., Cataliotti, A., & Burnett, J. C. J. (2002) · Circulation Research · doi:10.1161/hh0202.103613 · Cited by 89
RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials
von Lueder, T. G., & Krum, H. (2012) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-012-6424-y · Cited by 87
Self-citationLekawanvijit, S., Kompa, A. R., Zhang, Y., Wang, B. H., Kelly, D. J., & Krum, H. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00967.2011 · Cited by 86
Self-citationCurrent role of neprilysin inhibitors in hypertension and heart failure
von Lueder, T. G., Atar, D., & Krum, H. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.05.002 · Cited by 76
Self-citationNew roles for renin and prorenin in heart failure and cardiorenal crosstalk
Schroten, N. F., Gaillard, S., van Veldhuisen, D. J., Szymanski, M. K., Hillege, H. L., & de Boer, R. A. (2011) · Heart Failure Reviews · doi:10.1007/s10741-011-9262-2 · Cited by 72
Hegde, L. G., Yu, C., Renner, T., Thibodeaux, H., Armstrong, S. R., Park, T., Cheruvu, M., Olsufka, R., Sandvik, E., Lane, C. E., et al. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318210fc7e · Cited by 65
Luepker, R. V., Steffen, L. M., Jacobs, D. R., Zhou, X., & Blackburn, H. (2012) · Circulation · doi:10.1161/circulationaha.112.098517 · Cited by 45
Bäcklund, T., Palojoki, E., Saraste, A., Grönholm, T., Eriksson, A., Lakkisto, P., Vuolteenaho, O. J., Nieminen, M. S., Voipio‐Pulkki, L., Laine, M., et al. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00721-6 · Cited by 29
Palaniyappan, A., Uwiera, R. R. E., Idikio, H., & Jugdutt, B. I. (2008) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-9905-3 · Cited by 22
Kjeldsen, S. E., Hedner, T., Narkiewicz, K., & Oparil, S. (2012) · Blood Pressure · doi:10.3109/10582452.2012.741765 · Cited by 7
Cited by
Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology
Forrester, S. J., Booz, G. W., Sigmund, C. D., Coffman, T. M., Kawai, T., Rizzo, V., Scalia, R., & Eguchi, S. (2018) · Physiological Reviews · doi:10.1152/physrev.00038.2017 · Cited by 1,095
Azevedo, P. S., Polegato, B. F., Minicucci, M. F., Paiva, S. A. R., & Zornoff, L. A. M. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160005 · Cited by 475
Packer, M. (2018) · Circulation · doi:10.1161/circulationaha.117.032474 · Cited by 263
Metadata
- Authors
- von Lueder, T. G., Wang, B. H., Kompa, A. R., Huang, L., Webb, R., Jordaan, P., Atar, D., & Krum, H.
- Venue
- Circulation: Heart Failure
- Published
- 2015-01
- Volume
- 8
- Issue
- 1
- Pages
- 71-78
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W2116655536
- Cited by
- 290
- References
- 30
- FWCI
- 14.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.